Navigation Links
Ikaria(R) Named Private Company of the Year by New Jersey Technology Council
Date:11/21/2008

CLINTON, N.J., Nov. 21 /PRNewswire/ -- Ikaria Holdings, Inc. today announced that it has been named Private Company of the Year by the New Jersey Technology Council (NJTC), a 1,200-member non-profit organization that provides business support, networking opportunities, information and advocacy for technology companies and their leaders. Ikaria earned the award based on criteria including market leadership and unique product/service provision.

"We are delighted that the New Jersey Technology Council has recognized Ikaria for its leadership and innovation in critical care medicine," said Daniel Tasse, President and CEO of Ikaria. "This award is a testament to the hard work and pioneering spirit of our organization to deliver novel treatments for patients with unmet medical needs within the underserved critical care market."

Ikaria was honored at the NJTC Awards Gala on November 20, 2008, an annual black-tie event that attracts over 500 attendees. The NJTC Awards was founded in 1996 to publicly recognize and celebrate some of the most successful companies in the New Jersey technology community.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative pharmaceuticals and drug-device combinations for hospitalized, critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Australia and Latin America. INOmax recently was approved for marketing in Japan. Ikaria is engaged in new and ongoing clinical development of INOmax, Covox(R) (carbon monoxide) for inhalation and hydrogen sulfide. Recently, Ikaria acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit www.ikaria.com.

1. INOmax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOmax may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, thus may cause airway inflammation and damage. Methemoglobin, NO2, and Fi2 should be monitored during nitric oxide administration.

For more information on INOmax, including important safety information and full prescribing information, please visit www.inomax.com.

    CONTACTS

    Samina Bari                                  Jason Rando/Jen Saunders
    Ikaria                                       The Ruth Group
    (908) 238-6372                               (646) 536-7025/7011
    samina.bari@ikaria.com                       jrando@theruthgroup.com
                                                 jsaunders@theruthgroup.com


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Aspirin Named 8th World Wonder by Majority of Americans
2. American Board of Internal Medicine President Named to Alzheimers Study Group
3. New York Infection Prevention Expert Named Recipient of Carole DeMille Award
4. Pharmaxis Establishes Named Patient Program for Bronchitol
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
7. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
8. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
9. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
10. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
11. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
(Date:3/27/2017)... , March 27, 2017 ... to better understand Bayer and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... in Wethersfield, Conn., has relocated its corporate headquarters to a new, more expansive ... , In October 2016, Qualidigm purchased a distressed office building in Wethersfield, ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process Analytics ... power plant water and steam. , Chlorides and sulfates cause pitting and stress ... extensive maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels has ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder ... few medical professionals in the country to sit on the 2017 National Advisory Board ... just 2 years Dr. Harper helped propel the clinic from a small start-up to ...
(Date:3/28/2017)... ... 28, 2017 , ... Prominant bariatric surgeon and well-known weight-loss ... offer the recently FDA-approved Obalon Balloon System to his patients. The Obalon is ... already comprehensive list of weight-loss services. Dr. Liu is proud to announce ...
(Date:3/28/2017)... ... , ... With expansion and efficiency in mind, Patten Seed Company completed relocation ... plant opened in Marshallville in 2006, and a bagging and shipping facility has been ... of Patten Seed operations to the Middle Georgia location from their previous home in ...
Breaking Medicine News(10 mins):